Repligen Corporation RGEN
Set alert
At close · Oct 30
After hours · Oct 30, 4:30 PM ET
- YTD
- +7.98%
- 1 year
- +22.39%
- Open
- 175.37
- Prev close
- 188.64
- Mkt cap
- 11.23B
- Vol
- 4.47M
- Avg vol
- 1.13M
- EPS
- -0.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 171.23
- High
- 180.31
- Forward P/E
- 66.84
- Beta
- 1.08
- Short ratio
- 5.48
- Inst. own
- 106.45%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 178.12
- 200-d avg
- 144.69
- 1y target
- 202.22
Key statistics
- Market cap
- 11.23B
- Enterprise value
- 10.52B
- Trailing P/E
- 0.00
- Forward P/E
- 66.84
- PEG ratio
- 1.88
- Price / sales
- 13.94
- Price / book
- 4.80
- EPS (TTM)
- -0.21
- Beta
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -1.47%
- Revenue (TTM)
- 805.61M
- Revenue growth
- 10.90%
- Free cash flow
- 111.58M
- Total cash
- 862.98M
- Total debt
- 692.24M
- Return on equity
- -0.56%
- Shares outstanding
- 63.49M
- Short % of float
- 11.28%
- 50-day average
- 178.12
- 200-day average
- 144.69
Analyst view
Consensus: buy
- Target (low)
- 175.00
- Target (mean)
- 202.22
- Target (high)
- 235.00
- Strong buy3
- Buy14
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.52773.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.55 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 0.4628 | 0.53 | +0.07 | +14.52% |
| Jul 28, 2026 | Jun 30, 2026 | 0.447 | 0.54 | +0.09 | +20.81% |
| May 5, 2026 | Mar 31, 2026 | 0.38 | 0.48 | +0.10 | +26.32% |
| Feb 24, 2026 | Dec 31, 2025 | 0.44 | 0.49 | +0.05 | +11.36% |
| Oct 28, 2025 | Sep 30, 2025 | 0.42 | 0.46 | +0.04 | +9.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 19, 2026 | Canaccord Genuity | main | Hold | Hold |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Sep 9, 2026 | UBS | main | Buy | Buy |
| Jul 30, 2026 | Wells Fargo | main | Overweight | Overweight |
| Jul 29, 2026 | JP Morgan | main | Overweight | Overweight |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- repligen.com
News
- Repligen To Issue $1B Of 0.25% Convertible Senior Notes Due 2031 As Part Of Exchange, With ~$541.4M Of New Notes Issued In Exchange For ~$456.8M Of 2028 Notes And ~$458.6M Of New Notes Issued For Cash
- Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
- Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
- RBC Capital Maintains Outperform on Repligen, Raises Price Target to $200
- Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
- What Repligen (RGEN) Said on Its Q3 Earnings Call
- Conestoga Small Cap Composite Q3 2026 Portfolio Activity
- Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
- Repligen Q3 2026 Earnings Call Transcript
- Repligen Raises FY2026 Adj EPS Guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 Est; Raises FY2026 Sales Guidance from $813.000M-$835.000M to $844.000M-$852.000M vs $829.693M Est
Your note
Sign in to keep a note on RGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BYLUND JAMES | Chief Operating Officer | Stock Award(Grant) | Mar 4, 2026 | 25,423 |
| DAWES KAREN A | Director | Stock Award(Grant) | May 13, 2026 | 92,816 |
| DOUGLASS BRIAN ROBB | Officer | Stock Award(Grant) | Oct 5, 2026 | 8,685 |
| GARLAND JASON K. | Chief Financial Officer | Sale | Jul 15, 2026 | 18,829 |
| HUGHES VIOLETTA | Officer | Stock Award(Grant) | Mar 4, 2026 | 6,331 |
| HUNT ANTHONY JOHN | Director | Sale | Nov 12, 2025 | 83,695 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.54% | 5,384,938 | 952.81M | Jun 29, 2026 |
| FMR, LLC | 5.89% | 3,326,690 | 588.62M | Jun 29, 2026 |
| United Capital Financial Advisors, LLC | 4.94% | 2,790,650 | 493.78M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.27% | 2,411,171 | 426.63M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.10% | 2,312,825 | 409.23M | Jun 29, 2026 |
| Maverick Capital Ltd. | 3.52% | 1,984,554 | 351.15M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 2,010,262 | 355.70M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.02% | 1,702,844 | 301.30M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 1,229,445 | 217.54M | Jun 29, 2026 |
| MFS Series Trust IV-MFS Mid Cap Growth Fund | 1.85% | 1,044,165 | 184.75M | Aug 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.71% | 963,028 | 170.40M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.26% | 709,041 | 125.46M | Jun 29, 2026 |